Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Harley-Davidson Inc (HOG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Harley-Davidson Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $26.2 (market cap $4.49B), while Harley-Davidson Inc trades at $26.08 (market cap $2.73B). The key difference: ACADIA Pharmaceuticals Inc. is the larger of the two by market cap, and Harley-Davidson Inc pays a 2.84% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | HOG | |
|---|---|---|
Market Cap | $4.49B | $2.73B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $31.03 |
52-Week Low | $20.06 | $17.19 |
Enterprise Value | $3.69B | $3.12B |
Dividend Yield | — | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Harley-Davidson (HOG) trades at $25.89, up 3.73% today, with mixed technical signals showing bullish moving averages but neutral oscillators. Fundamentally, the company faces revenue declines from $5.8B in 2022 to $4.5B in 2025, though valuation ratios remain attractive with P/E of 13.12 and P/B of 0.87. Recent Q1 2026 earnings missed expectations at $0.22 vs. $0.34, but Q2 results are anticipated on July 23, 2026. Positive developments include production returning to the US and cost-cutting initiatives.
The outlook is cautious with analyst consensus at Hold (65.71%) and price target of $23.20 below current price. Risks include ongoing margin pressure, competitive threats, and execution of turnaround plans. Upside potential exists if cost savings and US production boost profitability, but investors should monitor Q2 earnings for confirmation of operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →
